Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial
Year: 2026
Type: article
Abstract: Background Rifampicin-based tuberculosis preventive therapy (TPT) may shorten treatment duration, but substantial interindividual pharmacokinetic variability may lead to different safety and tolerability profiles at the same dose. We performed pharmacokinetic/pharmacodynamic analyses of standard- and high-dose rifampicin to predict safety, completion, and tolerability. Methods We analyzed data from 1368 adults and adolescents enrolled in the 2R2 trial comparing 2 months of rifampicin at 20 or 30 mg/kg/day with 4 months at 10 mg/kg/day. A population pharmacokinetic model developed from 440 participants was used to predict rifampicin exposure for all participants. Missing exposure metrics were imputed using 1000 simulated datasets. Exposure-response relationships were evaluated using multivariable logistic regression models fitted within imputed datasets, with coefficients and standard errors pooled across imputations. Results A 2-fold increase in total rifampicin exposure (AUC0-24) was associated with higher odds of protocol-defined adverse events (AEs) requiring permanent discontinuation (aOR 1.88, 95% CI 1.25–2.81), discontinuation unrelated to AEs (aOR 1.42, 95% CI 1.15–1.75), and tolerability symptoms potentially related to AEs without discontinuation (aOR 1.48, 95% CI 1.18–1.86); similar patterns were observed for peak concentration (Cmax). Higher AUC0-24 and Cmax were also associated with grade 1–2 and grade 3–4 AEs, rash/allergy/hypersensitivity, gastrointestinal intolerance, and early discontinuation, with no significant association for hepatotoxicity. Exposure-based models showed slightly better discriminatory performance than dose-based models in predicting safety. Conclusions Higher rifampicin exposure was associated with worse safety, completion, and tolerability in TPT. Larger efficacy trials are needed to determine the optimal dose to achieve sufficient exposure, alongside investigation of therapeutic drug monitoring to avoid excessive exposure. Clinical Trials Registration The 2R2 trial was registered at https://clinicaltrials.gov/, identifier: NCT03988933.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag647
Authors: Fajri Gafar, Elin M Svensson, Vycke Yunivita, Federica Fregonese, Dina Fisher, Greg J Fox, Thu Anh Nguyen, Binh Hoa Nguyen, James Johnston, Richard Long, Lika Apriani, Chantal Valiquette, Rob E Aarnoutse, Rovina Ruslami, Dick Menzies, the 2R2 trial investigators, Leila Barss, Rachel K Lim, Nancy Bedingfield, Andrea Benedetti, Diana Gibson, Victor Chiang, Victoria J Cook, Eri Flores, Catherine Paulsen, Nguyen Viet Nhung
Institutions: Research Institute of the McGill University Health Centre, McGill University, Padjadjaran University, Uppsala University, Radboud University Medical Center, University of Calgary, The University of Sydney, Woolcock Institute of Medical Research, Hanoi Lung Hospital, Bệnh viện Phổi Trung ương, University of British Columbia, BC Centre for Disease Control, University of Alberta, McGill University Health Centre, Montreal Chest Institute
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
Funders: U.S. Department of Health and Human Services, United States Agency for International Development, Bill and Melinda Gates Foundation, Sanofi, Alberta Health Services, McGill University, British Columbia Lung Association, University of Alberta, University of Sydney, Fonds de recherche du Québec, Canadian Institutes of Health Research, Medical Research Council, National Health and Medical Research Council
OpenAlex ID: W7236576877
